Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical giants in the world’s second-largest healthcare market
The mov
Continue Reading on South China Morning Post
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.